Treatment and Prognosis of Adult T Cell Acute Lymphoblastic Leukemia.
10.3881/j.issn.1000-503X.10807
- Author:
Zou Fang HUANG
1
;
Ting Yu WANG
1
;
Ming Wei FU
1
;
Wei LIU
1
;
Mu HAO
1
;
Lu Gui QIU
1
;
De Hui ZOU
1
Author Information
1. Department of Lymphoma Center,State Key Laboratory of Experimental Hematology,Institute of Hematology and Blood Diseases Hospital,CAMS and PUMC,Tianjin 300020,China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Disease-Free Survival;
Female;
Hematopoietic Stem Cell Transplantation;
Humans;
Male;
Middle Aged;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
diagnosis;
therapy;
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;
diagnosis;
therapy;
Prognosis;
Remission Induction;
Retrospective Studies;
Survival Rate;
Treatment Outcome;
Young Adult
- From:
Acta Academiae Medicinae Sinicae
2019;41(4):485-491
- CountryChina
- Language:Chinese
-
Abstract:
To analyze the treatment and prognosis of T cell acute lymphoblastic leukemia(T-ALL)in adults. Method The clinicobiogical and survival data of 68 adult patients with newly diagnosis T-ALL were retrospectively analzyed. Results The median age of these 68 patients was 23 years(14-60 years).T-ALL was more common in men(81%).After the first cycle of treatment,complete remission was achieved in 50 patients(73%).The highest complete remission(CR) rate was in patients with cortex T-ALL(100%),followed by other T-ALL(73%)and early T-cell precursor lymphoblastic leukemia(54%),(=5.712,=0.058).The CR rate for adults aged >35 years was significantly lower than that of patients aged ≤ 35 years(40% 79%,=6.364,=0.012).The overall CR rate after the second treatment course was 93%.For patients treated with chemotherapy,autograft hematopoietic stem cell transplantation(auto-SCT),and allogeneic SCT,the median relapse free survival was 10 months,24 months,and not reached,respectively(=0.002).The 5-year overall survival rate was 25% for all patients;for patients treated with chemotherapy,auto-SCT and allogeneic SCT,the median overall survival was 24 months,34 months,and 30 months,respectively(=0.007),and the 5-year overall survival rate was 9%,33%,and 38%(=0.037).Multivariate analysis showed leukocyte count ≥100×10 /L was a risk factor for decreased relapse free survival(risk ratio 2.540,95%=1.058-6.099,=0.037). Conclusion Adult T-ALL patients have poor prognosis,which may be improved by SCT.
